Orbus Pharma Inc.

Orbus Pharma Inc.

October 26, 2006 18:03 ET

Orbus Patent Applications Published

TORONTO, ONTARIO--(CCNMatthews - Oct. 26, 2006) - Orbus Pharma Inc. (TSX:ORB) ("Orbus") today announced that patent applications for its instant release formulation of the drug fluvastatin has been published by the United States Patent and Trade-mark Office and the World Intellectual Property Office, the latter of which represents the potential for formalized patent applications in over 125 countries worldwide.

Fluvastatin, a cholesterol reducer, is one of the world's leading products used in the treatment of atherosclerosis vascular disease. The Orbus formulation is a generic version of Lescol® from Novartis AG, which has reported annual sales of this product in 2005 of US$767 million.

Orbus Pharma Inc., listed on The Toronto Stock Exchange under the symbol ORB. Orbus pursues a strategy of generating revenue through the licensing of generic drug developments, as well as the manufacturing and selling of pharmaceutical products. For more information please visit www.orbus.ca.

Forward looking statements

Certain statements in this disclosure are "forward-looking statements", which reflect management's expectations regarding the Company's future growth, results of operations, performance and business prospects and opportunities. Such forward-looking statements reflect management's current beliefs and are based on information currently available to management. Many factors could cause results to differ materially from the results discussed in the forward-looking statements, including risks related to dependence on key suppliers, economic conditions, competition, regulatory change, foreign exchange rates, and interest rates, among others. Although the forward-looking statements are based on what management believes to be reasonable assumptions, the Company cannot assure investors that actual results will be consistent with these forward-looking statements.

Contact Information

  • Orbus Pharma Inc.
    Jeffrey W. Renwick
    President & CEO
    (905) 943-9444